A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Combination to Lixisenatide on Top of OADs in Japanese Patients With Type 2 DM With an Extension Period
Phase of Trial: Phase III
Latest Information Update: 17 Jul 2018
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary) ; Lixisenatide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LIXILAN JP-O1
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 10 Jul 2018 Status changed from active, no longer recruiting to completed.
- 08 Nov 2017 Status changed from recruiting to active, no longer recruiting.